ImmunityBio (IBRX) Profit After Tax (2014 - 2026)

ImmunityBio (IBRX) has reported Profit After Tax for 13 consecutive years, with -$632.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 388.01% year-over-year to -$632.8 million; the TTM figure through Mar 2026 stood at -$854.5 million (down 108.83% YoY), while the FY2025 annual figure was -$351.4 million, up 15.05% from the prior year.
• Profit After Tax eased to -$632.8 million in Q1 2026 per IBRX's latest filing, from -$61.9 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$59.2 million in Q4 2024 and bottomed at -$632.8 million in Q1 2026.
• Historically, Profit After Tax has averaged -$141.1 million across 5 years, with a median of -$108.3 million in 2022.
• Annual changes were most pronounced in 2024 — Profit After Tax surged 74.64% — and 2026, when it tumbled 388.01%.
• ImmunityBio's Profit After Tax stood at -$108.3 million in 2022, then plunged by 115.45% to -$233.4 million in 2023, then soared by 74.64% to -$59.2 million in 2024, then fell by 4.57% to -$61.9 million in 2025, then tumbled by 922.53% to -$632.8 million in 2026.
• Business Quant data shows IBRX's Profit After Tax at -$632.8 million in Q1 2026, -$61.9 million in Q4 2025, and -$67.3 million in Q3 2025.